Biofrontera Inc. (NASDAQ:BFRI) is a biopharmaceutical company that commercializes products for dermatological conditions. The company recently reported its first-quarter 2026 financial results, which presented a mixed picture for investors, highlighted by a significant earnings miss but also strong underlying revenue growth and operational improvements.
On May 14, 2026, Biofrontera Inc. reported a quarterly loss of $0.41 per share. This result was wider than the consensus analyst estimate of a $0.12 loss. However, it marks an improvement from the $0.47 per share loss reported in the same quarter of the previous year, showing a smaller loss year-over-year.
The company also posted revenue of $10.08 million for the period. This figure fell slightly short of the analyst expectation of $10.25 million. Despite this, as highlighted by GlobeNewswire, the revenue represents a 17% increase from the $8.60 million recorded in the first quarter of 2025, indicating strong sales growth.
Operationally, Biofrontera Inc. demonstrated notable progress. Its gross margin, which is the profit made on sales before accounting for other business expenses, improved substantially to 80%. This gain is credited to a new strategic agreement. The company’s operating loss also narrowed to $4.30 million from $4.50 million a year prior.
Key financial ratios offer further insight. The company's Price-to-Earnings (P/E) ratio is -1.03, which is common for companies that are not yet profitable. Furthermore, its Debt-to-Equity ratio of 1.27 indicates that the company relies more on debt than on shareholder equity to finance its assets.
